

After undergoing the LightTouch test, 96 percent of women surveyed favored the LightTouch as a method for locating the presence of disease and reducing the number of biopsies, according to a study published in the *Journal of Lower Genital*



The LightTouch device is designed for portability and for use in many settings.

4955 Avalon Ridge Parkway  
Suite 300  
Norcross, GA 30071 USA

Phone: 770-242-8723  
Fax: 770-242-8639  
E-mail: [info@guidedinc.com](mailto:info@guidedinc.com)  
[www.guidedinc.com](http://www.guidedinc.com)

## Point-of-Care, Non-invasive Cervical Disease Detection

The LightTouch™ Cervical Neoplasia Detection System is designed to be a faster, more efficient way of accurately detecting disease of the cervix that may lead to cancer. Unlike Pap or HPV tests, the non-invasive LightTouch does not require a tissue sample or laboratory analysis, and results are available immediately. The LightTouch may be used for screening or in conjunction with a Pap or HPV test to help the physician determine if a biopsy is necessary.

Developed in collaboration with leading cervical cancer experts, the LightTouch uses proven enhanced imaging technology to scan the cervix and detect morphological and biochemical abnormalities that indicate cervical precancer and cancer. Almost 3,000 women have been tested using the technology with results presented at international conferences and multiple articles in leading peer-reviewed cervical disease journals. Development of the technology is supported by approximately \$6.0 million in grants from the National Cancer Institute. U.S. FDA pivotal trial is complete and the company has filed the first of three modules of the PMA application. The company has also been granted authority to attach the CE mark to the device. Initial product launch is expected in international markets where the need for early detection is high.

### LightTouch Features —

- Point of care with immediate results
- No tissue sample
- Painless
- Physician or technician operated
- Proven spectroscopic technology
- Single-patient-use disposable reduces cost of device and prevents cross infection
- Touch screen technology

### What Do Experts at the U.S. National Cancer Institute Say?

“This type of early detection should lead to health care cost savings due to the significant difference in treatment cost between high-grade cervical precancer and Stage 1 or higher cancer.”

“The commercial potential for a viable optical diagnostic for cervical precancers is substantial. Garnering even a small portion of the screening market would mean substantial sales of instruments and related supplies/disposables.”

“The potential societal impact is also great. The limitations of the PAP smear are widely accepted and the reduction of healthcare costs currently incurred because of false positives would be significant. The ability to perform in situ diagnostics would also serve to reduce patient anxiety.”

“Societal importance of this project is high. The low specificity and sensitivity numbers of current practice result in a large number of patients undergoing unnecessary biopsy and/or a large number of patients with cancer going untreated. The proposed technology addresses this diagnostic need.”

“The ... instrument is an innovative approach to multimode imaging, providing both imaging and spectroscopy... The degree of integration of these various aspects of bringing a new technology is impressive and indicated an eventual pay off greater than the sum of the individual components.”

“The team is excellent, highly experienced and well balanced.”



Dr. Daron Ferris of the Medical College of Georgia



Clinical Trials at the Medical College of Georgia